3 First-Line Indolent Trial (FIT) in
Monday, 5:00 #631-III Radioimmunotherapy with 90Y-
Dec. 10, PM (3412) Ibritumomab Tiuxetan (Zevalin)
2007 as Consolidation of First Remission
in Patients with Advanced Stage
Follicular Lymphoma: A Real-Time MBR
Monday, 5:00 #664-III CHOP-R (Cyclophosphamide,
Dec. 10, PM (3445) Doxorubicin, Vincristine, Prednisone,
2007 Rituximab) Compared to CPOP-R
Vincristine, Prednisone, Rituxamib)
in First-Line Therapy of Diffuse
Large B Cell Lymphoma (DLBCL): An
For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference Web site at http://www.hematology.org.
ZEVALIN(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.
Deaths associated with an infusion reaction symptom complex have
occurred within 24 hours of rituximab infusions. Yttrium-90 ZEVALIN
administration results in severe and prolonged cytopenia
|SOURCE Cell Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved